Bosch Prostate Cancer Focus Group
Lab head: Chris Murphy
Location: F13 - Anderson Stuart Building
Lab members: S Assinder (senior), Q Dong (senior), C Murphy (senior), J Reichardt (senior), D Richardson (senior)
Prostate cancer and benign prostatic hyperplasia
Primary supervisor: Stephen Assinder
Our research is focused on:
- Understanding how the loss of structural proteins involved in organization of the cell cytoskeleton contribute to the development of prostate cancer phenotypes.
- Hormone regulation of prostate cell proliferation. In particular we are interested in how oxytocin, a hormone usually associated with females, regulates enzymes that are essential to growth of the prostate and to determine if different cell signal pathways are involved.
Dysregulation of receptor tyrosine kinase signalling antagonists leads to prostate cancer.
Our recent research (Assinder et al., 2015) indicates that a co-repression of Sprouty and Spred, antagonists of FGF signalling, is associated with the progression of prostate cancer. It is likely, due to the need for tight regulation of receptor tyrosine kinase signalling, that having a family of SPRY and SPRED negative regulators provides a degree of redundancy. Until now, this has not been considered in the context of prostate cancer.
The aim of this project is to demonstrate in vitro that compound loss of SPRY2 and SPRED2 induces an aggressive cancer phenotype. This project will employ many techniques including cell culture of normal human prostate and prostate cancer cell lines, RT-PCR, real time PCR, siRNA knockdowns, western blots, flow cytometry, growth, proliferation and phenotypic assays.
This project is in collaboration with Prof Frank Lovicu, Discipline of Anatomy and Histology.
Projects are available in these areas of interest. They will employ many techniques including cell culture, proliferation assays, RT-PCR, real time PCR, siRNA knock downs, Western blot, Immunohistochemistry, thin layer chromatography and radioimmunoassay.